Key result
Fusing human IgG Fc to EV71 VP1 protein increased secretion levels and demonstrated the most potent immunogenicity in mice compared to other VP1 constructs (P<0.05).
p-value: p=<0.05
Fusing human IgG Fc to the EV71 VP1 protein enhances its secretion and immunogenicity, suggesting a promising strategy for EV71 DNA vaccine development.
Enterovirus (EV71) can cause severe neurological diseases, but the underlying pathogenesis remains unclear. The capsid protein, viral protein 1 (VP1), plays a critical role in the pathogenicity of EV71. High level expression and secretion of VP1 protein are necessary for structure, function and immunogenicity in its natural conformation. In our previous studies, 5 codon-optimized VP1 DNA vaccines, including wt-VP1, tPA-VP1, VP1-d, VP1-hFc and VP1-mFc, were constructed and analyzed. They expressed VP1 protein, but the levels of secretion and immunogenicity of these VP1 constructs were significantly different (P<0.05). In this study, we further investigated the protein levels of these constructs and determined that all of these constructs expressed VP1 protein. The secretion level was increased by including a tPA leader sequence, which was further increased by fusing human IgG Fc (hFc) to VP1. VP1-hFc demonstrated the most potent immunogenicity in mice. Furthermore, hFc domain could be used to purify VP1-hFc protein for additional studies.
No takes yet. Share an insight, caveat, or question.
A 2016 study studied Enterovirus 71 (EV71). VP1-hFc DNA vaccine vs. Other VP1 DNA vaccines (wt-VP1, tPA-VP1, VP1-d, VP1-mFc) was evaluated on Secretion levels and immunogenicity (p=<0.05). Fusing human IgG Fc to EV71 VP1 protein increased secretion levels and demonstrated the most potent immunogenicity in mice compared to other VP1 constructs (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: